Status:
COMPLETED
Myocardial Perfusion Magnetic Resonance Imaging Using Regadenoson
Lead Sponsor:
Washington University School of Medicine
Collaborating Sponsors:
Astellas Pharma US, Inc.
Conditions:
Ischemic Heart Disease
Eligibility:
All Genders
18+ years
Phase:
EARLY_PHASE1
Brief Summary
This is a pilot study to determine whether the drug regadenoson can be used during magnetic resonance imaging to assess regions of poor blood flow to the heart. The hypothesis of this study is that a...
Detailed Description
This is a pilot study that proposes to assess the feasibility of using regadenoson (Lexiscan, Astellas), a recently FDA approved A2A receptor agonist, as the stress perfusion agent in cardiac MRI perf...
Eligibility Criteria
Inclusion
- reversible perfusion abnormalities on a clinically ordered rest/adenosine dual-isotope SPECT-MPI in at least 2 contiguous myocardial segments (per 17-segment model)
Exclusion
- myocardial infarction, myocardial revascularization procedure or progression in angina occuring after the SPECT-MPI examination
- pregnancy
- gadolinium-based MR contrast allergy
- glomerular filtration rate (GFR) \> 60 mL/min/1.73 m2
- contraindications to MR imaging (pacemaker, brain aneurysm clips, schrapnel, etc.)
Key Trial Info
Start Date :
June 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2011
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT00881218
Start Date
June 1 2009
End Date
December 1 2011
Last Update
April 10 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Washington University School of Medicine
St Louis, Missouri, United States, 63110